Key result
CMV seropositive myocardial infarction patients had elevated levels of PAI-1 and IL-6, and lower levels of MMP-3 compared to CMV seronegative patients.
Why the study?
CMV may reactivate in atherosclerotic plaques and associate with cardiovascular mortality, but whether CMV seropositivity and IgG levels correlate with relevant biomarkers after MI was unclear.
Does CMV seropositivity correlate with altered levels of inflammatory and metabolic biomarkers in patients with prior myocardial infarction?
Case-Control (n=324)
Does CMV seropositivity correlate with altered levels of inflammatory and metabolic biomarkers in patients with prior myocardial infarction?
CMV seropositivity is associated with an enhanced inflammatory and prothrombotic biomarker profile in patients recovering from myocardial infarction.
Answers are grounded in this paper and cite their sources.
May flag heightened post-MI inflammation in CMV-seropositive patients; hypothesis-generating and requires prospective trials before clinical consideration.
• Equal CMV seroprevalence in MI patients and controls. • CMV seropositive patients had higher levels of PAI-1 and IL-6 compared to −negative. • Weak positive correlation between CMV IgG levels and PAI-1 in MI patients. • CMV seropositivity was associated with higher proinsulin but not diabetes diagnosis. • Results suggest an enhanced inflammatory state in CMV seropositive patients after MI. Efforts to understand atherosclerosis, a major cause of ischemic heart disease, have linked several lifestyle factors to increased risk for developing cardiovascular disease. Some studies suggest that cytomegalovirus (CMV), a widely prevalent herpesvirus, is reactivated in atherosclerotic plaques and associated with higher cardiovascular mortality risk. We aimed to explore whether CMV seropositivity and CMV-IgG antibody levels correlate with relevant biomarkers in a cohort of patients with myocardial infarction (MI) and matched controls. We analyzed a dataset from 324 survivors of MI treated in Stockholm between 1996 and 2001. Blood samples collected three months after MI were used to measure protective Apo B100 autoantibodies, metabolic, and inflammatory biomarkers. CMV serology was performed on stored serum samples. Correlation analyses were conducted between biomarkers and CMV serostatus in 324 patients and age- and sex-matched controls. While CMV seroprevalence was equal, the CMV-IgG levels were higher in controls. Among various factors examined, CMV seropositive MI patients had elevated levels of plasminogen activator inhibitor-1 (PAI-1) and interleukin-6, along with lower levels of MMP-3, than CMV seronegative MI patients. CMV-IgG levels correlated positively with PAI-1 levels in patients. Although CMV seropositivity was associated with increased proinsulin levels, there was no correlation with diabetes diagnosis. Our findings suggest an enhanced inflammatory and prothrombotic state in CMV seropositive patients after MI. Notably, patients had lower levels of CMV IgG than controls.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2024) conducted a case-control in Myocardial infarction (n=324). Cytomegalovirus (CMV) seropositivity vs. CMV seronegativity was evaluated on Levels of inflammatory and metabolic biomarkers (PAI-1, IL-6, MMP-3). CMV seropositive myocardial infarction patients had elevated levels of PAI-1 and IL-6, and lower levels of MMP-3 compared to CMV seronegative patients.
Synapse has enriched 10 related papers. Consider them for comparative context: